Drug Profile
FK 778
Alternative Names: HMR 1715; MNA 715; X 920715Latest Information Update: 05 Jul 2006
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Astellas Pharma
- Class Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Liver transplant rejection; Multiple sclerosis; Renal transplant rejection; Transplant rejection
Most Recent Events
- 30 Jun 2006 Discontinued - Preclinical for Autoimmune disorders in Germany (unspecified route)
- 30 Jun 2006 Discontinued - Preclinical for Multiple sclerosis in Germany (unspecified route)
- 30 Jun 2006 Discontinued - Phase-II for Liver transplant rejection in Europe (PO)